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Myocardin, a coactivator of serum response factor (SRF), plays a critical role in the differentiation of
vascular smooth muscle cells (SMCs). However, the molecular mechanisms regulating myocardin stability and
activity are not well defined. Here we show that the E3 ligase C terminus of Hsc70-interacting protein (CHIP)
represses myocardin-dependent SMC gene expression and transcriptional activity. CHIP interacts with and
promotes myocardin ubiquitin-mediated degradation by the proteasome in vivo and in vitro. Furthermore,
myocardin ubiquitination by CHIP requires its phosphorylation. Importantly, CHIP overexpression reduces
the level of myocardin-dependent SMC contractile gene expression and diminishes arterial contractility ex
vivo. These findings for the first time, to our knowledge, demonstrate that CHIP-promoted proteolysis of
myocardin plays a key role in the physiological control of SMC phenotype and vessel tone, which may have an
important implication for pathophysiological conditions such as atherosclerosis, hypertension, and Alzhei-
mer’s disease.
Phenotypic modulation of vascular smooth muscle (SM)
cells (SMCs) plays a pivotal role in vascular development and
remodeling during diseases. It is well established that the SMC
phenotype is regulated by a wide range of extracellular cues. In
response to vascular injury, vascular SMCs (VSMCs) dediffer-
entiate to a proliferative phenotype that is required for the
various pathological states in atherosclerosis, neointimal hy-
perplasia, and hypertension (27, 28). VSMC differentiation is
characterized by expressing the highest levels of SM contractile
genes, whereas proliferating SMCs express reduced levels of
these genes. Thus, changes in SM contractile gene expression
are often used to mark SMC phenotypes. It has been known
that most SM contractile genes such as SM -actin, SM myosin
heavy chain (SM-MHC), and SM22 are controlled by serum
response factor (SRF), which binds to a sequence known as a
CArG box (18, 28). The specific genes activated by SRF are
determined by the intracellular signals, as well as the availabil-
ity of positive and negative cofactors. One of these factors is
the SRF cofactor myocardin, which activates SRF-dependent
genes and functions as a “master regulator” of SMC differen-
tiation during development (31, 32, 36).
Myocardin is expressed specifically in SM and cardiac mus-
cle lineages and belongs to a SAP (SAF-A/B, acinus, PIAS)
superfamily which has been implicated in cardiovascular de-
velopment and adaptation of the cardiovascular system to he-
modynamic stress (18, 28). Myocardin physically interacts with
the MADS box transcription factor SRF, activating a subset of
genes involved in cardiomyocyte and SMC differentiation in
vivo (32). Recent reports from myocardin gain- and loss-of-
function studies demonstrate that it is necessary and sufficient
to initiate SMC differentiation (32). One study by Huang et al.
shows that myocardin conditional mutant mice exhibit mark-
edly diminished expression of SMC contractile proteins in the
ductus arteriosus and a generalized defect in neural crest-
derived SMC differentiation (14). Furthermore, several studies
suggest that the expression and function of myocardin in SMC
differentiation are tightly modulated, at least in part, via the
RhoA/Rho kinase pathway (22, 24, 38). Recently, PIAS1 has
been reported to regulate myocardin transactivity via its ligase-
induced sumoylation (17). Phosphorylation of myocardin by
GSK-3 also represses its transactivation and cardiomyocyte
hypertrophy (2). However, the posttranslational mechanisms
regulating myocardin protein stability and transcriptional ac-
tivity in SMCs are not fully understood.
Increasing evidence suggests that chaperones and the ubiq-
uitin (Ub)-proteasome system are responsible for maintaining
the cell environment free from toxic misfolded proteins. One
link that connects chaperones and the Ub-proteasome machin-
ery is the chaperone-associated Ub ligase CHIP (C terminus of
Hsc70-interacting protein). CHIP is most highly expressed in
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human striated muscle, aortic SMCs, endothelial cells, and
other tissue cells (4). It has been shown that CHIP works in the
protein quality control machinery at different levels and targets
a number of Hsp70/90-associated substrates or aggregation-
prone proteins for degradation by the proteasome (1, 7, 8, 15,
25, 39). Thus, these observations indicate that CHIP plays an
important role in the regulation of cell growth, apoptosis, and
neurodegeneration. It is still not clear, however, whether CHIP
FIG. 1. Overexpression of CHIP inhibits myocardin-induced SMC differentiation through downregulation of myocardin protein. (A) SMCs
were transfected with CHIP or the empty vector for 24 h and then cultured in 2% horse serum for 48 h. The transcripts of SM genes, including
those for SM22, SM -actin, SM-MHC, smoothelin, myocardin, and SRF, were examined by RT-PCR. (B) Quantitative analysis of the mRNA
levels in panel A (n  3, means  SEM). *, P  0.01 versus the vector. (C) SMCs were transfected with myocardin, WT CHIP, and U-box deletion
mutant plasmids. Cells were cultured, and the mRNA levels of SM genes were analyzed as in panel A. (D) Quantitative analysis of mRNA
transcripts in panel C (n  3, means  SEM). *, P  0.01 versus myocardin alone. (E) SMCs were transfected with CHIP or vector plasmids and
cultured in 2% horse serum for 0, 12, 24, 36, 48, or 60 h. The cell extracts were examined with antimyocardin, anti-CHIP, or -actin antibody.
(F) SMCs were transfected with increasing amounts of CHIP plasmid and cultured in 2% horse serum for 48 h. The cell extracts were examined
as in panel E. (G, H) 293 cells were transfected with myocardin, SM22, or ANF reporters and increasing amounts of WT CHIP or CHIP U-box
(0.25 and 0.5 g). Luciferase (Luc) activity was measured (n  3, means  SEM). *, P  0.01 versus myocardin alone. GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; Wt, wild type.
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plays a physiological role in SMC differentiation and vessel
tone. This prompted us to explore the possibility that CHIP is
involved in the phenotypic modulation of VSMCs. Here we
show that CHIP inhibits myocardin-dependent SMC gene
expression and transcriptional activity. Furthermore, CHIP
promotes phosphorylated myocardin ubiquitination and deg-
radation by the proteasome, thereby inhibiting myocardin-de-
pendent SMC differentiation and arterial tone.
MATERIALS AND METHODS
Plasmids, antibodies, and reagents. The expression plasmids containing wild-
type (WT) and mutant CHIP and myocardin, His-Ub, hemagglutinin (HA)-SRF,
the active form of GSK-3 S9A (Ac-GSK3), the dominant-negative form of
GSK-3 S9A (Dn-GSK-3), CHIP small interfering RNA (siRNA), control
siRNA, and SM22- and ANF-luciferase reporters have been described previ-
ously (4, 6, 15, 31, 35). The antibodies used were anti-Flag antibody (M2;
Sigma-Aldrich); anti-CHIP, anti-Myc (clone 9E10), and antimyocardin antibod-
ies (Santa Cruz Biotechnology); anti-HA antibody (Roche); anti-Ub, anti-His,
anti-GST, and anti--actin antibodies (Chemicon International Inc.); and anti-
GSK-3, anti-Hsp70, anti-Hsp90, and anti-mouse or anti-rabbit conjugated an-
tibodies (Cell Signaling). MG132 and AR-A014418 were purchased from Cal-
biochem. Acetylcholine, phenylephrine, and sodium nitroprusside (SNP) were
obtained from Sigma-Aldrich.
Cell culture and luciferase assays. SMCs were isolated from the aortic media
of 4-month-old male Sprague-Dawley rats and cultured as previously described
(12). 293T and A10 cells were obtained from ATCC (Manassas, VA) and cul-
tured in Dulbecco modified Eagle medium supplemented with 10% fetal calf
serum, penicillin, and streptomycin at 37°C as described previously (20, 21).
Transfection of cells was performed with Lipofectamine 2000 (Invitrogen) trans-
fection reagent according to the protocol of the manufacturer.
Luciferase activity was assayed with the Luciferase Assay System (Promega) as
described previously (20, 21). The data represent the means  the standard
errors of the means (SEM) of three independent experiments in triplicate and
normalization to ß-galactosidase activity.
RNA analysis. Total RNA was purified from cultured cells or arterial tissues
with Trizol. SM gene analysis of SM22, SM -actin, SM-MHC, myocardin,
SRF, smoothelin, and glyceraldehyde-3-phosphate dehydrogenase by reverse
transcription (RT)-PCR was performed with primers designed to detect rat gene
products as described previously (1, 23, 31). The relative quantities of mRNA
were normalized against glyceraldehyde-3-phosphate dehydrogenase.
Immunoprecipitations, Western blotting, and GST pull-down assays. Immu-
noprecipitation and immunoblotting were performed as described previously
(20). Glutathione S-transferase (GST), GST-CHIP, and its mutant forms were
prepared, and GST pull-down assays were performed as described previously (4).
The FLAG-myocardin and corresponding deletion mutant proteins were ex-
pressed in 293 cells. The blots were developed with a chemiluminescence system,
and the bands were scanned and densitometry analysis was performed with a
Gel-pro 4.5 analyzer (Media Cybernetics).
Immunofluorescence. Full-length myocardin cDNA was inserted into the
green fluorescent protein (GFP) fusion vector pEGFP-C1 (Clontech) to create
plasmid pEGFP-myocardin. Plasmids expressing Myc-CHIP and GFP-myocar-
din were cotransfected into A10 cells. After 24 h, cells were processed for
immunofluorescence staining with the primary antibody (anti-Myc, 1:50 dilution)
overnight at 4°C and an Alexa Fluor 488-conjugated secondary antibody (1:500
dilution). Samples were observed with a confocal microscope (20, 21).
Nickel-agarose chromatography and ubiquitination assays in vivo. Cells were
transfected with the indicated plasmids and lysed in Ni-agarose lysis buffer (50
mM NaH2PO4, 300 mM NaCl, 5 mM imidazole, 0.05% Tween 20, 10 mM
N-ethylmaleimide, complete protease inhibitor). Ub-conjugated proteins were
purified by nickel chromatography (Ni-nitrilotriacetic acid-agarose; Qiagen) and
detected by immunoblotting with anti-Flag or anti-His antibody (21). Ubiquiti-
nation in vivo was assayed as described previously (20).
Degradation assays. To analyze the degradation kinetics of myocardin, 293T
cells were seeded in six-well plates and transfected with myocardin and CHIP or
the pcDNA3.1 vector as indicated. Protein lysates were prepared at the indicated
time points after the addition of cycloheximide (50 g/ml). The levels of myo-
cardin were determined by immunoblotting, quantified at the indicated time
points, and normalized to -actin (20, 21).
In vitro ubiquitination reactions. For CHIP-mediated ubiquitination, Flag-
myocardin or mutant protein (amino acids [aa] 1 to 713) was precipitated from
transfected 293 cells in the presence or absence of the GSK-3 inhibitor AR-
A014418 (6 h) with 2 g of anti-Flag antibodies. Purified Flag-myocardin and
mutant protein (aa 1 to 713) were incubated in 20 l of Ub reaction buffer–100
ng of E1–500 ng of UbcH5b–5 g of Ub in the presence of bacterially purified
GST only, GST-CHIP, or GST–CHIP U-box (1 g). After incubation at 30°C
for 2 h, reaction products were analyzed by immunoblotting with the indicated
antibodies as described previously (20).
Rat arterial contractility assays. The thoracic aorta was isolated from anes-
thetized 2-month-old Sprague-Dawley rats by an approved institutional protocol
according to Beijing Union Medical College guidelines. Aortic rings (4 mm in
length) were mounted on 25-m stainless steel wires in the chambers of a
myograph (Danish Myo Technology A/S Inc.) in Krebs buffer (glucose at 5.5
mmol/liter, NaCl at 118.5 mmol/liter, KCl at 4.7 mmol/liter, MgSO4 at 1.2
mmol/liter, KH2PO4 at 1.2 mmol/liter, NaHCO3 at 25 mmol/liter, 37°C) gassed
with 95% O2/5% CO2 at pH 7.4 and 37°C. The precontraction state of each aortic
ring was determined by running a concentration-response curve for phenyleph-
rine to establish maximum contraction. For relaxation studies with acetylcholine
and SNP, rings were precontracted with phenylephrine at 80% maximum con-
traction as described previously (5, 26).
Transduction of aortic rings ex vivo. Aortic segments were incubated in a
96-well plate at 37°C for 2 h with a viral suspension containing 3 	 108 PFU of
adenovirus (Ad)-GFP or Ad-CHIP. Expression of GFP in the transduced carotid
arteries was confirmed by observing fluorescence on fresh-frozen artery sections
(10 m) with a microscope (Nikon E600). For Western blot analysis, rings were
rinsed twice with ice-cold phosphate-buffered saline and then lysed. Fifty micro-
grams of lysate was run on an 8% gel for the detection of myocardin and CHIP.
-Actin was used as a control for protein loading. The levels of SM22, SM--
actin, and SM-MHC mRNAs in aortic rings were determined as described in the
section on RNA analysis.
FIG. 2. CHIP siRNA upregulates the expression of myocardin-
induced SM contractile genes. (A) SMCs were transfected with control
or CHIP siRNA and cultured in 2% horse serum for 48 h. CHIP and
myocardin mRNA and protein levels were analyzed by RT-PCR and
immunoblotting as indicated. (B) SMCs were transfected and cultured
as in panel A. The transcripts of SMC genes, including those for
SM22, SM -actin, SM-MHC, and myocardin, were examined by
RT-PCR. (C) Quantitative analysis of the mRNA transcripts in panel
B (n  3, means  SEM). *, P  0.05 versus control siRNA. (D) SMCs
were transfected with SM22 reporter, control siRNA, or CHIP
siRNA for 48 h. Luciferase (luc) activity was measured (n  3,
means  SEM). *, P  0.01 versus control siRNA. GAPDH, glycer-
aldehyde-3-phosphate dehydrogenase.
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Statistical analysis. Data are presented as means  SEM. Differences be-
tween groups were evaluated with Student t tests. Concentration-response data
were fitted to a logistic function by nonlinear regression and analyzed by a
two-way analysis of variance. P values of less than 0.05 were regarded as signif-
icant.
RESULTS
CHIP represses the induction of myocardin-dependent SM
contractile genes through downregulation of myocardin pro-
tein. To investigate the role of CHIP in SMC differentiation,
we first examined whether CHIP alters the expression of SM
contractile genes. SMCs were transfected with CHIP plasmid,
and the mRNA levels of SM contractile genes were quantified
by RT-PCR. Transfection of cells with CHIP markedly de-
creased myocardin-induced SMC gene expression compared
with that in control cells. Importantly, CHIP did not affect the
mRNA levels of myocardin and myocardin-independent genes,
including smoothelin and SRF (Fig. 1A and B). These results
demonstrate that CHIP specifically inhibits myocardin-depen-
dent SMC differentiation.
To examine whether Ub ligase activity is required for this
effect, we coexpressed myocardin and WT CHIP or U-box
deletion mutant CHIP (CHIP U-box, loss of E3 ligase activ-
ity) and found that transfection with WT CHIP resulted in a
marked inhibition of myocardin-dependent gene expression
(SM22, SM -actin, and SM-MHC) compared with the con-
trol, whereas CHIP U-box failed to page myocardin-induced
gene expression (Fig. 1C and D), indicating that this effect is
dependent on the E3 ligase activity of CHIP.
We next tested whether CHIP could regulate the stability of
myocardin protein. SMCs were transfected with a CHIP plas-
mid for the indicated times of differentiation. The expression
of myocardin sharply increased and reached its maximal level
at 12 h but then gradually declined to a lower level until the
completion of differentiation (Fig. 1E). Moreover, overexpression
of CHIP decreased the level of endogenous myocardin in a dose-
dependent manner (Fig. 1F), suggesting that CHIP downregu-
lates the expression of myocardin at the protein level.
To further confirm that CHIP could directly inhibit myocar-
din-dependent transcriptional activity, luciferase assays were
performed with SM22 and ANF promoters. As shown in Fig.
1G and H, overexpressing myocardin strongly activated these
promoters. However, when WT CHIP was expressed at the
same time, this induction was dramatically reduced in a dose-
dependent manner, whereas CHIP U-box was unable to re-
press myocardin-dependent gene transcriptional activity, indi-
cating that the U-box domain is required for the inhibitory
effect of CHIP on myocardin transactivation. Taken together,
these data demonstrate that CHIP serves as a negative regu-
lator of SMC differentiation through downregulation of myo-
cardin protein and this effect is also dependent on its E3 ligase
activity.
FIG. 3. CHIP interacts with myocardin. (A) SMCs were cultured in 2% horse serum for 48 h, lysates were immunoprecipitated with anti-CHIP
antibody or control IgG, and the immunoprecipitates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immuno-
blotted (IB) with antimyocardin (top) or anti-CHIP (bottom) antibody. (B) SMCs were cultured in 2% horse serum for 48 h. Cell lysates were
subjected to coimmunoprecipitation (IP) with antimyocardin or anti-CHIP antibody in the absence or presence of ATP (10 mM) and rabbit IgG
as a control. The presence of CHIP, Hsp70, Hsp90, or myocardin in the precipitated complexes was determined by immunoblotting as indicated.
(C) CHIP interacts with myocardin in GST pull-down assays. GST fusion proteins were analyzed by immunoblotting with anti-GST antibody (top).
The ability of Flag-myocardin (middle) or HA-SRF (bottom) expressed in 293 cells to be retained by GST or GST-CHIP fusion protein was
analyzed by immunoblotting after binding reactions. (D) 293 cells were transfected with the indicated plasmids. Equal amounts of protein lysates
were immunoprecipitated with the anti-Myc or control IgG serum and analyzed by immunoblotting with anti-Flag or anti-Myc antibody. (E) SMCs
were cotransfected with Myc-CHIP and GFP-myocardin and immunostained with anti-Myc antibody. For quantitation, 150 cells per coverslip were
counted and each treatment was performed in triplicate. A representative image is shown for each condition.
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CHIP siRNA enhances the expression of SM contractile
genes. To further test the involvement of endogenous CHIP in
the modulation of SMC differentiation, siRNA was used to
inhibit endogenous expression of CHIP in SMCs. CHIP knock-
down resulted in a moderate increase in the level of myocardin
protein but no change in mRNA expression (Fig. 2A). More-
over, transfection of SMCs with CHIP siRNA also increased
the expression of SM contractile genes, including SM22, SM-
-actin, and SM-MHC, compared with transfection with con-
trol siRNA (Fig. 2B and C). Furthermore, transfection of
SMCs with increasing amounts of CHIP siRNA resulted in a
marked increase in SM22 promoter activity compared with
that obtained with control siRNA (Fig. 2D). These findings
suggest that endogenous CHIP plays a role in controlling the
expression of myocardin-dependent SM contractile genes.
CHIP interacts with myocardin. It has been known that one
of the characteristics of an E3 kinase is the recognition of
specific substrates. Next we examined whether endogenous
CHIP interacts with myocardin in differentiated SMCs. The
myocardin protein was detected in the immune complex pre-
cipitated with anti-CHIP antibody (Fig. 3A) and formed a
complex with Hsp70/Hsp90 through CHIP in the absence or
presence of ATP in SMCs (Fig. 3B), whereas no myocardin
was found in the immune complex precipitated with a nonspe-
cific immunoglobulin G (IgG) control (Fig. 3A and B). Also,
Flag-myocardin expressed in 293 cells was pulled down by
GST-CHIP fusion protein purified from bacteria but not be-
tween CHIP and SRF under this condition (Fig. 3C). Further-
more, immunoprecipitation analysis demonstrated that Flag-
myocardin was detected in the Myc-CHIP immune complex,
whereas no Flag-myocardin was found in control IgG (Fig.
3D). Finally, immunostaining indicated that CHIP was colo-
calized with myocardin in SMCs (Fig. 3E). Thus, myocardin
forms a complex directly with CHIP in vivo and in vitro.
To identify the domain of CHIP that mediates the interac-
tion with myocardin, a GST pull-down assay was performed
with a series of GST-CHIP deletion mutant proteins as indi-
cated. As shown in Fig. 4A and B, full-length CHIP (aa 1 to
303) bound strongly to myocardin and the U-box deletion
mutant protein (aa 1 to 197) had less of an effect on binding to
myocardin. However, the charged region deletion mutant pro-
tein (aa 1 to 142) failed to bind to myocardin in this assay,
indicating that the charged domain (aa 143 to 197) of CHIP is
required for binding to myocardin. Furthermore, the site of
myocardin interaction with CHIP was determined with a series
of truncated myocardin constructs and these assays demon-
strate that residues of 714 to 935, containing the C-terminal
transactivation domain (TAD) of myocardin, are necessary for
the interaction with CHIP (Fig. 4C and D).
CHIP promotes myocardin ubiquitination for proteasome
degradation. Because the expression pattern of myocardin pro-
tein is inversely correlated with CHIP in SMCs (Fig. 1E and F
and 2A) and CHIP formed a complex specifically with myo-
cardin both in vivo and in vitro (Fig. 3 and 4), we sought to
FIG. 4. Mapping of the interactive domain of CHIP and myocardin. (A) The domain of CHIP involved in binding to myocardin. GST fusion proteins
were analyzed by immunoblotting with anti-GST antibody (top). The ability of the truncated CHIP fusion proteins to bind to Flag-myocardin expressed
in 293 cells was analyzed by immunoblotting with anti-Flag antibody (middle). Ten percent of the input is shown in the bottom panel. (B) Schematic
representation of the CHIP mutant proteins used in panel A. (C) The domain of myocardin involved in binding to CHIP. GST-CHIP fusion proteins
were analyzed by immunoblotting with GST antibody (top). The ability of the truncated myocardin proteins expressed in 293 cells to bind to GST-CHIP
was analyzed by immunoblotting with anti-Flag antibody (middle). Ten percent of the input is shown in the bottom panel. (D) Schematic representation
of deletion constructs of myocardin used in panel C. TPR, tetratricopeptide repeat; Q, a stretch of glutamine residues; SAP, SAF-A/B–acinus–PIAS
domain; LZ, leucine zipper.
2402 XIE ET AL. MOL. CELL. BIOL.
ascertain whether the effect of CHIP on myocardin protein is
mediated through proteasome degradation. We first per-
formed a pulse-chase assay and found that ectopic expression
of CHIP resulted in a rapid decrease in myocardin protein
compared with the vector control (Fig. 5A). Furthermore,
transient expression of CHIP resulted in a marked reduction of
myocardin protein in SMCs and this effect was abolished by the
proteasome inhibitor MG132 (Fig. 5B).
To determine whether CHIP promotes the ubiquitination of
endogenous myocardin, a ubiquitination assay was performed
FIG. 5. CHIP as an E3 ligase targets myocardin for proteasomal degradation. (A) 293 cells were transfected with a Flag-myocardin, Myc-CHIP,
or vector plasmid and treated with cycloheximide (CHX, 10 g/ml) at the indicated time points. The half-life of myocardin was determined by
immunoblotting with anti-Flag antibody and quantified in the presence of a CHIP or vector plasmid (n  3, means  SEM). (B) The effect of CHIP
on steady-state levels of myocardin was examined by transfection with a Myc-CHIP or vector plasmid in the presence of MG132 for 4 h. (C) The
ubiquitination of endogenous myocardin in SMCs was tested by transfection with a Myc-CHIP or vector plasmid. Cell extracts were immuno-
precipitated (IP) with antimyocardin antibody and immunoblotted (IB) with an anti-Ub (top) or antimyocardin (middle) antibody. The expression
of myocardin and CHIP in the cell extracts was determined with antimyocardin or anti-Myc antibody (bottom). (D) 293 cells were transfected with
a His-Ub, Myc-CHIP, or CHIP U-box mutant plasmid in the presence of Flag-myocardin WT or mutant protein 1-713 and incubated with MG132
for 4 h before harvesting. Ub-conjugated proteins were purified by nickel chromatography and analyzed by immunoblotting with anti-Flag (top)
or anti-His (middle) antibody. The expression of myocardin and CHIP in the cell extracts was determined with anti-Flag or anti-Myc antibody
(bottom). (E) In vitro ubiquitylation reactions were performed with purified Ub, E1, E2-Ubc5b, GST alone, GST-CHIP, and GST–CHIP U-box
mutant protein in the presence of Flag-myocardin WT or 1-713 mutant protein. Reaction products were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, followed by immunoblotting with anti-Ub (top) or anti-Flag antibody (bottom).
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with SMCs and myocardin-specific antibody. Coexpression of
CHIP indeed induced the formation of high-molecular-weight
species that can be recognized by anti-Ub antibody in the
myocardin immunoprecipitates (Fig. 5C). Furthermore, CHIP
E3 ligase activity was required for Ub conjugation to myocar-
din since myocardin ubiquitination was abrogated to a large
degree by coexpression with a ligase-inactive mutant protein
(CHIP U-box) compared with WT CHIP (Fig. 5D, compared
lane 4 with lane 5). As expected, myocardin lacking the TAD
(mutant protein 1-713) was resistant to CHIP-mediated ubiq-
uitination (Fig. 5D, lane 6).
To further confirm that CHIP can mediate myocardin ubiq-
uitination in vitro, we reconstituted a reaction with the immu-
noprecipitated Flag-myocardin, GST-CHIP, GST–CHIP U-
box, and recombinant E1 and UbcH5b (29). Reactions were
performed with Flag-myocardin expressed in 293T cells as a
substrate. Consistent with in vivo results, ubiquitination of
myocardin was detected in the presence of GST-CHIP (Fig.
5E, lane 6) whereas this effect was abolished by a U-box dele-
tion in CHIP (Fig. 5E, compare lane 5 with lane 6). Further-
more, myocardin mutant protein 1-713, which lacks the CHIP-
binding region, markedly attenuated the CHIP-induced
ubiquitination of myocardin (Fig. 5E, compare lane 7 with lane
6). In addition, omitting E1, UbcH5b, Ub, or GST-CHIP ab-
rogated the formation of poly-Ub chains (lanes 1 to 4). Col-
lectively, these data indicate that CHIP functions as an E3
ligase and that the U-box domain of CHIP and the CHIP-
binding region (TAD) of myocardin are both required for
myocardin ubiquitination and degradation by the proteasome
in vivo and in vitro.
CHIP ubiquitinates phosphorylated myocardin in vivo and
in vitro. It has been reported that myocardin protein is phos-
phorylated by GSK-3 (2). To test whether myocardin ubiq-
uitination by CHIP requires its phosphorylation in vivo, 293
cells were transfected with His-Ub, Flag-myocardin, and Myc-
CHIP and treated with AR-A014418, which is a known GSK-
3-specific inhibitor. Transfection with CHIP promoted myo-
cardin ubiquitination in the absence of AR-A014418 but not in
the presence of AR-A014418 treatment (Fig. 6A), and the
ubiquitination of myocardin was reduced by AR-A014418
treatment in a dose-dependent manner (Fig. 6B). To further
test whether overexpressing GSK-3 affects the ubiquitination
of myocardin, 293 cells were transfected with Flag-myocardin,
Myc-CHIP, Flag-Ub, Ac-GSK-3, or Dn-GSK-3 and treated
with the proteasome inhibitor MG132 for 4 h before harvest-
ing. As shown in Fig. 6C, CHIP-mediated ubiquitination of
myocardin was dramatically enhanced by Ac-GSK-3 whereas
Dn-GSK-3 substantially paged the effect of CHIP. We then
examined whether recombinant GST-CHIP ubiquitinates
phosphorylated myocardin in vitro in the presence of E1,
UbcH5b, and Flag-myocardin expressed in 293 cells pretreated
without or with AR-A014418. Indeed, CHIP-mediated ubiq-
uitination of myocardin was detected as high-molecular-weight
bands by immunoblotting with anti-Ub in the absence of AR-
A014418 whereas treatment with AR-A014418 abolished this
effect (Fig. 6D, compare lane 2 with lane 1). Taken together,
these results suggest that CHIP specifically ubiquitinates phos-
phorylated myocardin for degradation in vivo and in vitro.
CHIP gene transfer ex vivo reduces the expression of SMC
contractile genes and contractility. Because myocardin gene
overexpression was associated with elevated contractile protein
expression and contractility in cerebral VSMCs (5) and CHIP
expression is inversely associated with myocardin protein level
and its transactivation (Fig. 1 and 2), we hypothesized that
overexpressing CHIP would reduce myocardin-dependent
SMC contractile gene expression and contractility. Rat aortic
rings were transduced ex vivo with Ad-CHIP or Ad-GFP, and
the expression of contractile genes and the responses of trans-
duced vessels to acetylcholine, phenylephrine, or SNP were
examined. As shown in Fig. 7A, efficient gene transfer to the
SMC layer of arteries, as indicated by GFP, was observed and
Ad-CHIP transduction markedly decreased the expression of
myocardin protein and SMC contractile genes compared with
FIG. 6. CHIP promotes the ubiquitination of phosphorylated myo-
cardin. (A) 293 cells were transfected with His-Ub, Flag-myocardin,
and Myc-CHIP and left untreated or treated with AR-A014418 (10
mM) for 12 h in the presence of MG132 for 4 h before harvesting. Cell
extracts were immunoprecipitated (IP) with the anti-Flag antibody and
immunoblotted (IB) with the anti-His (top) or -Flag (middle) anti-
body. Cell extracts were subjected to immunoblotting with anti-Flag or
anti-Myc antibody (bottom). (B) 293 cells were transfected with His-
Ub, Flag-myocardin, and Myc-CHIP plasmids and treated with in-
creasing amounts of AR-A014418 (0, 5, and 10 mM) for 12 h in the
presence of MG132 for 4 h before harvesting. Cell extracts were
immunoprecipitated and immunoblotted as in panel A. (C) 293 cells
were cotransfected with vectors expressing His-Ub, Flag-myocardin,
Myc-CHIP, GSK-3 S9A, or Dn-GSK in the presence of MG132 for
4 h before harvesting. Ub-conjugated proteins were purified by nickel
chromatography and analyzed by immunoblotting with anti-Flag (top)
and anti-His (middle) antibodies. The expression of myocardin, CHIP,
and GSK-3 in the cell extracts was determined with anti-Flag, anti-
Myc, or anti-HA antibody (bottom). (D) In vitro ubiquitination reac-
tions were performed with purified Ub, E1, E2-UbcH5b, GST alone,
or GST-CHIP. Flag-myocardin was precipitated from transfected 293
cells treated with AR-A014418 or left untreated for 12 h. Reaction
products were analyzed as described in the legend to Fig. 5E.
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Ad-GFP controls in aortic rings (Fig. 7B to D). Consistent with
these findings, in Ad-CHIP arteries, contractions in response
to phenylephrine, a direct VSMC vasoconstrictor (3), were
significantly reduced compared with those in Ad-GFP controls
(Fig. 8A). In contrast, endothelium-dependent relaxations in
response to acetylcholine were markedly increased (Fig. 8B).
Furthermore, the effects of SNP, a nitric oxide donor that
causes endothelium-independent VSMC relaxation (3), were
also examined in vessels denuded of endothelium. As shown in
Fig. 8C, SNP-mediated relaxations of Ad-CHIP-transduced
rings in response to SNP were increased compared with those
of Ad-GFP controls. These results suggest that CHIP is in-
volved in the regulation of the SMC contractile phenotype in
rat aortic rings.
DISCUSSION
The cellular level of myocardin protein determines both its
transcriptional activity and its responsiveness. The function of
myocardin is regulated through a number of factors and sig-
naling pathways (18, 28). However, the molecular mechanisms
that regulate myocardin-mediated SMC differentiation and
contractility are not fully elucidated. In the present study, we
have investigated the relationship between CHIP and myocar-
din and its relevance for SMC differentiation and contractility.
We clearly show that CHIP expression dramatically decreases
myocardin stability and inhibits myocardin-dependent SMC
differentiation through Ub-mediated degradation. The phos-
phorylation state is required for the ubiquitination of myocar-
din by CHIP. Importantly, CHIP gene transfer reduces the
myocardin-mediated SMC contractile phenotype and arterial
contractility.
CHIP was first identified as a protein that interacts with the
C terminus of Hsp70 and shown to negatively regulate Hsp70
chaperone activity (4). Subsequently, CHIP was demonstrated
to be a Ub ligase of the U-box family (4, 16). CHIP contains
three major structural domains—a three-tetratricopeptide re-
peat domain that allows it to interact with chaperones such as
Hsc70/Hsp70 and Hsp90, a charged domain, and a U-box do-
main that confers E3 Ub ligase activity on this cochaperone (4,
16). Recent studies have demonstrated that CHIP has a critical
regulatory function in the protein quality control machinery of
cells (4, 6, 9, 16) and is responsible for the misfolding-depen-
dent ubiquitination and degradation of the glucocorticoid hor-
mone receptor, ErbB2, cystic fibrosis transmembrane conduc-
tance regulator, androgen receptor, Ask1, p53, Tau, and ataxin
1 proteins (1, 7, 8, 10, 11, 15, 25, 39). Therefore, CHIP appears
to play an important role in targeting chaperone-protein com-
plexes to the proteasome. In this study, our data showed that
CHIP expression dramatically decreased myocardin stability
and inhibited myocardin-dependent SMC differentiation.
Moreover, CHIP physically interacted with myocardin in vitro
and in vivo and the charged region of CHIP was required for
binding to myocardin. Furthermore, CHIP promoted myocar-
din ubiquitination and degradation by the proteasome and this
process was dependent on its E3 ligase activity. These findings
demonstrate that the cellular myocardin protein level is tightly
controlled by CHIP-dependent proteasomal degradation. Im-
portantly, CHIP-mediated degradation of myocardin repre-
FIG. 7. CHIP gene transfer downregulates myocardin protein level and SM contractile gene expression in rat aortic rings. (A) Expression of
GFP in aortic rings 2 days after transduction of Ad-GFP and Ad-CHIP was confirmed with a fluorescence microscope (magnification, 	40).
(B) Myocardin and CHIP levels were determined by Western blot analysis. The blots are typical representatives of two different rings per group.
(C) The expression of SM contractile gene mRNAs was detected by RT-PCR analysis. (D) Quantitative analysis of mRNA levels in panel C.
Means  SEM of four rings per group are shown. *, P  0.01 versus Ad-GFP.
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sents a previously uncharacterized mechanism of inactivation
of this SRF coactivator during SMC phenotype modulation.
In several cases, the target transcriptional factor proteins
were first marked by phosphorylation for ubiquitination. For
example, I
B and -catenin were phosphorylated by GSK-3
and then ubiquitinated by the Skp1/cullin 1/F-box complex (30,
37). Tau was also phosphorylated by GSK-3 and targeted to
proteasomal degradation by CHIP (7, 19, 29). In the case of
myocardin, its relevance for diverse physiological events in the
posttranslational modifications, including phosphorylation and
sumoylation, has been well investigated (2, 33, 34). Myocardin
protein is known to be phosphorylated by GSK-3. In contrast,
GSK-3 pageade enhances myocardin-induced ANF transcrip-
tion levels (2). In postphosphorylation, however, the fate of
myocardin proteins remains unclear. In the present study,
treatment with the GSK-3-specific inhibitor AR-A014418
showed an inhibitory effect on the ubiquitination level of myo-
cardin. Furthermore, cotransfection of Ac-GSK-3 resulted in
a significant increase in CHIP-induced ubiquitination of myo-
cardin whereas dominant-negative GSK-3 had an inhibitory
effect. These results indicate that CHIP selectively recognizes
and ubiquitinates phosphorylated myocardin in vivo and in
vitro. Thus, it is not surprising that increased levels of CHIP,
activated GSK3, or both can accelerate the ubiquitination of
myocardin.
Abnormal expression of SMC contractile genes and prolif-
eration of VSMCs contribute to the various pathological states
in atherosclerosis, hypertension, Alzheimer’s disease, and the
response to vascular injury (18). The expression of SM marker
genes is regulated by the CArG box sequence and activities of
SRF/myocardin (13). Although myocardin functions as a tran-
scriptional coactivator that plays a critical role in SMC differ-
entiation (32, 35), it is not fully understood whether myocardin
can promote VSMC contractility. A recent study reported that
elevated SRF/myocardin activity exhibits an Alzheimer’s
disease-like hypercontractile phenotype in human cerebral
VSMCs and alters arterial vasodilation and contractility (5). In
contrast, myocardin conditional mutant mice show a dramatic
FIG. 8. CHIP overexpression regulates the contractile phenotype in rat aortic rings. Shown are concentration-response curves for phenyleph-
rine (A), acetylcholine (B), and SNP (C) in rat aortic rings transduced for 2 days with Ad-GFP (n  4) or Ad-CHIP (n  4). Means  SEM from
four rings per group are shown. *, P  0.01 versus Ad-GFP. (D) Schematic model depicting the role of CHIP in SMC phenotype modulation via
promoting myocardin degradation.
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decrease in SMC contractile protein expression and a gener-
alized defect in VSMC differentiation (14). These data place
myocardin at a critical nodal point required for maintenance of
the contractile SMC phenotype and contractility. However, it
remains unclear what the physiological role of CHIP is in
regulating the myocardin-mediated SMC phenotype and arte-
rial contractility. Our results show that overexpression of CHIP
in rat aortic rings markedly decreased the myocardin protein
level and inhibited the expression of SMC contractile genes
(Fig. 7B to D). Importantly, CHIP overexpression markedly
reduced phenylephrine-induced contractility whereas endothe-
lium-dependent and -independent relaxations in response to
acetylcholine and SNP were increased in isolated aortic rings
transduced with Ad-CHIP compared with those of Ad-GFP
controls (Fig. 8A to C). These results suggest that CHIP plays
a critical role in controlling the SMC phenotype and arterial
tone.
In conclusion, here we provide comprehensive evidence that
CHIP promotes the ubiquitination and degradation of phos-
phorylated myocardin by the proteasome. Through this mech-
anism, the effects of myocardin on SMC differentiation and
vessel contractility are abolished by CHIP. The proposed
mechanism is presented in Fig. 8D. Thus, the present study has
identified a novel mechanism of posttranslational regulation of
myocardin activity by CHIP that may open a new therapeutic
approach to atherosclerosis and other cardiovascular disor-
ders.
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